Novartis
Novartis AG, established in 1996 through the merger of Ciba-Geigy and Sandoz, is a Swiss multinational pharmaceutical corporation focused on developing, manufacturing, and marketing innovative medicines to address global health needs. The company operates as a leading entity in the life sciences sector, continually reshaping its portfolio to concentrate on high-growth, specialized therapeutic areas.
Quick Facts
- Founded
- 1996
- Founder
- Merger of Ciba-Geigy and Sandoz
- Origin
- Switzerland
Founders
Story Chapters
Timeline
Formation of Novartis
Novartis was formed through the merger of two Swiss companies, Ciba-Geigy and Sandoz, creating a pharmaceutical powerhouse.
Launch of Gleevec
Novartis launched Gleevec, a groundbreaking cancer treatment that revolutionized the approach to chronic myeloid leukemia.
Acquisition of Hexal and Eon Labs
Novartis expanded its generics business by acquiring Hexal and Eon Labs, solidifying its position in the generic pharmaceuticals market.
FDA Approval of Lucentis
Lucentis was approved by the FDA, offering a new treatment for wet age-related macular degeneration and transforming eye care.
Alcon Acquisition
Novartis completed the acquisition of Alcon, becoming a global leader in eye care and expanding its ophthalmology portfolio.
Launch of Entresto
Entresto was launched as a novel heart failure treatment, representing a significant advancement in cardiovascular medicine.
Spin-off of Alcon
Novartis spun off Alcon into an independent company, allowing both entities to focus on their core strengths and markets.
Acquisition of The Medicines Company
Novartis acquired The Medicines Company, enhancing its cardiovascular portfolio with the addition of inclisiran, a cholesterol-lowering drug.
COVID-19 Response Initiatives
Novartis responded to the COVID-19 pandemic with research, donations, and collaborations to support global health efforts.
Strategic Focus on Innovative Medicines
Novartis announced a strategic shift to focus on innovative medicines, prioritizing transformative therapies and cutting-edge research.
Connected Across The Archives
Explore specific connections to other archives—civilizations, conflicts, dynasties, and treaties that share history with this company.
Civilization Archive
(4)Austrian Empire
Novartis was founded amid the Austrian Empire's influence, a period marked by political and scientific developments shaping Central Europe.
European Union Civilization
Novartis operates under EU regulations, which harmonize pharmaceutical standards, crucial for its global market presence and innovation strategies.
Ottoman Empire
Novartis was established as the Ottoman Empire's decline reshaped geopolitical boundaries, influencing trade and market access in the region.
Swiss Confederation
Novartis emerged in Switzerland, a nation whose unique confederation model supported innovation and stability, fostering pharmaceutical advancements.
Explore Related Archives
Great companies don't emerge in a vacuum. They rise from the foundations of civilizations, the ambitions of rulers, and the aftermath of conflicts. Explore the historical context:
